Хондрофлекс

General characteristics. Structure:

Active ingredient: 250 mg of a glycosamine of a hydrochloride, 200 mg of chondroitin of sodium sulfate in 1 capsule.

Excipients: Mannitolum, magnesium stearate, croscarmellose sodium (primelloza), talc.

Gelatinous solid capsules (titanium dioxide, azoruby, Ponso 4R, gelatin, acetic acid, methylparahydroxybenzoate, пропилпарагидроксибензоат) (ND 42-10070-06).

Stimulates recovery of cartilaginous tissue.

Pharmacological properties:

Pharmacodynamics. Stimulates recovery of cartilaginous tissue. A glycosamine and chondroitin sulfate take part in synthesis of connecting fabric, promoting prevention of processes of destruction of a cartilage and stimulating fabric regeneration. Introduction of an exogenous glycosamine strengthens development of a cartilaginous matrix and provides nonspecific protection against chemical injury of a cartilage. The glycosamine in the form of sulphatic salt is a predecessor a hexosemine, and sulfate-anion is necessary for synthesis of glikozaminoglikan. Other possible function of a glycosamine is protection of the injured cartilage against the metabolic destruction caused by non-steroidal anti-inflammatory drugs (NPVP) and glucocorticosteroids (GKS) and also own moderate antiinflammatory action.

Chondroitin sulfate irrespective of whether it is soaked up in an intact form or in the form of separate components, serves as additional substrate for formation of a healthy cartilaginous matrix. Stimulates formation of a gialuronon, synthesis of proteoglycans and collagen like II, and also protects гиалуронон from zymolysis (by suppression of activity of hyaluronidase) and from the damaging action of free radicals; influences phosphorus-calcium exchange in cartilaginous tissue, slows down a resorption of a bone tissue and reduces calcium loss, accelerates processes of recovery of a bone tissue, slows down process of a degeneration of cartilaginous tissue, promotes recovery of a joint bag, the cartilaginous surfaces of joints, maintains viscosity of synovial fluid, plays a role of a peculiar lubricant of joint surfaces, participates in a reparation of a cartilage and suppresses activity of those enzymes which split a cartilage (elastase, hyaluronidase). At treatment of an osteoarthrosis facilitates symptoms of a disease and reduces the need for NPVP.

Pharmacokinetics. At intake of 90% it is soaked up from the digestive tract (DT). The maximum concentration in a blood plasma (Cmax) is reached in 3-4 h, in synovial fluid – in 4-5 h. Bioavailability in relation to synovial fluid:

- for chondroitin – 13%;

- for a glycosamine – 25% (the effect of "the first passing" through a liver is expressed).

At sodium sulfate chondroitin intake once (or 2 times a day in a dose of 0,4 g) concentration in plasma sharply increases in a dose of 0,8 g for 24 h. Absolute bioavailability – 12%.

The glycosamine + chondroitin sulfate is distributed in fabrics: the greatest concentration are found in a liver, kidneys and a joint cartilage. About 30% of the accepted dose are long persistirut in bone and muscular tissue. About 10 and 20% of the accepted dose are absorbed in the form of high-molecular and low-molecular derivatives, respectively. The seeming distribution volume – about 0,44 ml/g.

Chondroitin sodium sulfate is metabolized by means of desulphonation (after administration of low-molecular chondroitin of sodium sulfate). At distribution in fabrics the greatest concentration are found in a liver, kidneys and a joint cartilage. About 30% of the accepted dose are long persistirut in bone and muscular tissue. The glycosamine + chondroitin sulfate is removed preferential with urine in not changed look; partially - with a stake.

Elimination half-life (T1/2) for a glycosamine – 68 h. An elimination half-life (T1/2) for sulfate chondroitin – 310 min.

Indications to use:

Osteoarthrosis of peripheral joints and joints of a backbone of the I-III degree.

Route of administration and doses:

Inside, in 20 minutes prior to food, with a small amount of liquid. Appoint 2 capsules 3 times a day within the first three weeks; in the next days - on 2 capsules 2 times a day. The minimum course of reception makes 3 months.

Features of use:

1. Pregnant and feeding. Drug is contraindicated for use during pregnancy and breastfeeding. In need of use of drug in the period of a lactation breastfeeding is recommended to be stopped.

2. To children. Drug is contraindicated for use to children up to 18 years.

3. The adult with chronic diseases. Drug is contraindicated for use by the adult with the expressed disturbance of functions of kidneys.

Data on possible influence of medicine for a medical use on ability to manage vehicles, mechanisms. It is required to be careful when driving or working at which the increased concentration of attention and speed of psychomotor reactions as individual reaction to drug is not excluded are necessary.

With care to use drug at a diabetes mellitus, tendency to bleedings, bronchial asthma.

At emergence of undesirable effects from a GIT the dose of drug should be reduced twice, and in the absence of improvement – to cancel drug. In the absence of clinical effect after a medical course on 4 capsules a day within 4 weeks it is necessary to specify the diagnosis.

Not to exceed the dose recommended by the doctor.

The steady medical effect is reached at reception not less than 6 months.

Against the background of administration of drug the need for NPVP decreases.

Side effects:

Glycosamine: dysfunction of digestive tract (pain in epigastriums, a meteorism, diarrhea or a lock), dizziness, allergic reactions, a headache, an onychalgia and peripheral hypostases, drowsiness, sleeplessness, tachycardia.

Chondroitin: allergic reactions.

Interaction with other medicines:

Increases absorption of tetracyclines, reduces effect of semi-synthetic penicillin and a glycosamine.

Drug is compatible to NPVP and GKS.

Contraindications:

The increased individual sensitivity to one of drug components (allergic reaction), the expressed renal failure, pregnancy, the lactation period, children's age up to 18 years.

Dosing mode, way of introduction: inside, in 20 minutes prior to food, with a small amount of liquid. Appoint 2 capsules 3 times a day within the first three weeks; in the next days - on 2 capsules 2 times a day. The minimum course of reception makes 3 months.

Overdose:

Symptoms: cases of overdose are unknown.

Treatment: gastric lavage, symptomatic therapy.

Storage conditions:

In the dry place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children. A period of validity and the instruction on prohibition of use of medicine after a period of validity - 2 years. Not to use after the period of validity specified on packaging.

Issue conditions:

Without recipe

Packaging:

Capsules of 250 mg + 200 mg. On 5, 6, 10 capsules in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished or on 30, 60, 100 capsules in glass or polymeric jar. On 1, 2, 3, 4, 5, 6, 9, 10,12 blister strip packagings with the application instruction in a pack from a cardboard.